Last reviewed · How we verify

ALGINIC ACID

Phase 3 active Quality 32/100

ALGINIC ACID is a alginic acid drug. It is currently in Phase 3 development.

Alginic acid forms a protective barrier over the stomach lining to prevent stomach acid from causing irritation.

Alginic acid is a naturally occurring polysaccharide derived from brown seaweed, used as a medication to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. It works by forming a protective barrier over the stomach lining, preventing stomach acid from coming into contact with the esophagus and causing irritation. Alginic acid is a small molecule drug classified under the alginic acid drug class, but its commercial status and approved indications are unclear. As a naturally occurring substance, it is not patented, and its safety profile is generally considered favorable. However, more information is needed to confirm its pharmacokinetic properties and clinical efficacy.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameALGINIC ACID
Drug classalginic acid
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Imagine your stomach lining is like a delicate skin that can get irritated easily. Alginic acid works like a protective shield, covering the stomach lining and preventing stomach acid from coming into contact with it, which helps to reduce inflammation and discomfort.

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ALGINIC ACID

What is ALGINIC ACID?

ALGINIC ACID is a alginic acid drug.

How does ALGINIC ACID work?

Alginic acid forms a protective barrier over the stomach lining to prevent stomach acid from causing irritation.

What drug class is ALGINIC ACID in?

ALGINIC ACID belongs to the alginic acid class. See all alginic acid drugs at /class/alginic-acid.

What development phase is ALGINIC ACID in?

ALGINIC ACID is in Phase 3.

What are the side effects of ALGINIC ACID?

Common side effects of ALGINIC ACID include New Wound, Infections, Falls, Maceration, Wound Infection, Pain.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing